Posted on 04/22/2021 5:49:48 AM PDT by Cathi
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection.
Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing.
Clinical symptoms of Covid-19 developed 19 days after Patient 1 received the second dose of vaccine and 36 days after Patient 2 received the second dose. Both patients had histories consistent with a clinical response to vaccine boost.
In Patient 1, documented high titers of neutralizing antibodies were present shortly after the development of symptoms. Taken together, our observations support the conclusion that we have characterized bona fide examples of vaccine breakthrough manifesting as clinical symptoms. Moreover, data from Patient 1 indicate that infection with variant virus can be sustained with a high viral load despite high levels of neutralizing antibodies to variants.
(Excerpt) Read more at nejm.org ...
Thanks for posting. 3 days after his 2nd modeRNA jab, my friend DG was dead. R.I.P., DG.
“…infection with variant virus can be sustained with a high viral load despite high levels of neutralizing antibodies to variants.”
That sounds dire...then you read that both women had mild cases that resolved.
97% of covid patients have mild cases that resolve. Only 3% are hospitalized. These cases were not asymptomatic. They were typical covid cases.
.
“Two areas of concern relate to the ability of variants to evade vaccine-induced immunity and cause asymptomatic infection (and thereby promote viral spread) or illness. Both consequences are important, both need to be considered independently, and both are largely unknown.”
“We describe two fully vaccinated persons in whom subsequent breakthrough infections with SARS-CoV-2 variants harboring a number of substitutions of interest developed. Despite evidence that the first dose of vaccine led to a strong antibody response to spike protein in Patient 1, saliva-based polymerase-chain-reaction (PCR) screening at Rockefeller University identified infection 19 days after the second dose (the booster vaccination). Testing was also positive for infection in Patient 2, who had completed vaccination 36 days previously. Together, these observations provide support for current strategies to monitor multiple variables proactively. These strategies include viral testing of symptomatic and asymptomatic persons, sequencing of viral RNA, and monitoring of neutralizing antibody titers, particularly in vaccinated persons who subsequently become infected.”
2/417 = 0.5%. Much better than the 95% phase three human trial. I assume you are reporting this as good news?
What caused your friend to die? Was it a blood clot from the vaccine or some other side effect?
“Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection.
Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing.
Clinical symptoms of Covid-19 developed 19 days after Patient 1 received the second dose of vaccine and 36 days after Patient 2 received the second dose. Both patients had histories consistent with a clinical response to vaccine boost.”
“These observations in no way undermine the importance of the urgent efforts being taken at the federal and state levels to vaccinate the U.S. population. They also lend support to efforts to advance a new vaccine booster (as well as a pan-coronavirus vaccine) to provide increased protection against variants. In January 2021, Moderna announced clinical efforts to target a new variant of SARS-CoV-2 that was first identified in South Africa and includes three mutations (E484K, N501Y, and K417N) in the angiotensin-converting–enzyme 2 receptor-binding domain. These efforts are of critical value because recent studies have shown that immunizations are proving to be less potent against the variant first identified in South Africa (B.1.351), which might have acquired a partial resistance to neutralizing antibodies generated by natural infections or vaccinations.14,15 At the same time, our observations underscore the importance of the ongoing race between immunization and the natural selection of potential viral escape mutants. During this critical period, our data support the need to maintain layers of mitigation strategies, including serial testing of asymptomatic persons, open publication and analysis of vaccination and infection databases (such as those accruing data in New York City), and rapid sequencing of SARS-CoV-2 RNA obtained from a variety of high-risk persons.”
Previous post was errant.
No, it is definitely not good news.
First, your mathematical equation assumes that all 417 were exposed to covid. But, we know that isn’t true. We have no idea how many of those people were exposed to covid. That is why clinical trials that determine efficacy require a matching control group. Unless they had provided the covid numbers for the unvaccinated University employees we cannot determine a demominator.
Second, these vaccinated patients had a strong response to the vax and developed high titres of neutralizing antibodies, but nonetheless had a high viral load and full blown cases of covid.
Obviously the authors of the study consider their observations concerning and I agree with them.
Masks Forever!
btt
Notice they are called ‘breakthroughs’ rather than vaccine ‘failures’.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.